Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells


Investor Relations

NASDAQ : STML

$15.39 - 1.13
Volume: 321,800
Oct 31, 2014 4:00 PM ET
Delayed at least 20min., by eSignal.

Stock price graph
     

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk in a variety of cancer types. Stemline is currently developing two clinical-stage product candidates, SL-401 and SL-701.

SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R). A multicenter clinical trial with SL-401 is currently open and actively accruing patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and advanced acute myeloid leukemia (AML).  An additional clinical trial with SL-401 is currently open in patients with AML who are in first complete remission (CR) with minimal residual disease (MRD), which is associated with a high relapse rate. Stemline is also planning SL-401 trials in additional hematologic cancers including several uncommon, stem cell-derived myeloproliferative disorders. Previously, SL-401 demonstrated single-agent activity, including multiple durable complete responses (CRs), in a Phase 1/2 trial in several indications including BPDCN and relapsed/refractory AML.

SL-701 is an enhanced immunotherapy designed to activate the immune system to attack tumors. A multicenter clinical trial with SL-701 is currently open and actively accruing adult patients with glioblastoma multiforme (GBM) in first recurrence. Previously, an earlier version of the therapy demonstrated clinical activity, including durable CRs and partial responses (PRs), in Phase 1/2 trials in adults and children with advanced brain cancers.

Additionally, Stemline has built a robust preclinical pipeline, which includes next generation IL-3R-targeted compounds, SL-501 and SL-101, an innovative discovery platform, and an extensive intellectual property portfolio including some of the earliest patents in the CSC area.



Corporate Snapshot

PDF Corporate Snapshot


Corporate Presentation

PDF Corporate Presentation – October 2014

View all »   RSSRecent Releases

Oct 16, 2014
Stemline Therapeutics Initiates SL-401 Trial in AML Patients in First Complete Response With Minimal Residual Disease, the Second SL-401 Trial Initiated in 2H14

Sep 8, 2014
Stemline Therapeutics to Present at the Aegis Capital 2014 Healthcare & Technology Conference


View all »Events & Presentations

There are no upcoming events at this moment.



Copyright 2014 - Stemline Therapeutics, Inc. All rights reserved
Stemline